---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-000623"
form_type: "8-K"
ticker: "LIPO"
cik: "0001347242"
company_name: "LIPELLA PHARMACEUTICALS INC."
filed_at: "2025-04-14T23:59:59+00:00"
generated_at: "2026-05-23T15:22:18.438249+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lipella Pharmaceuticals regains Nasdaq equity compliance after $5.9M placement

## Summary
- Final closing of Series B convertible preferred stock offering on March 12, 2025; net proceeds ~$5.9M.
- Also issued warrants to purchase up to 72,000 Series B shares at $100/share on March 17, 2025; gross proceeds $9,000.
- Stockholders' equity was ~$1.9M as of Dec 31, 2024; after offerings, company believes it meets Nasdaq's Stockholders' Equity Requirement.
- Nasdaq continued listing is subject to compliance; company states it currently remains in compliance.

## SEC filing metadata
- accession: 0001753926-25-000623
- form_type: 8-K
- ticker: LIPO
- cik: 0001347242
- company_name: LIPELLA PHARMACEUTICALS INC.
- filed_at: 2025-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000623/0001753926-25-000623-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000623/g084773_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-000623
- JSON: https://secwatch.observer/filing/0001753926-25-000623.json
- Plain text: https://secwatch.observer/filing/0001753926-25-000623.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.